SCHEMBL3825925

SCHEMBL3825925

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CC2C(=O)NCc2ccccc2)c(C(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.51
PLAT P00750 1/20 0.51
F10 P00742 1/20 0.48
XIAP P98170 4/20 0.46
FKBP1A P62942 3/20 0.45
EPHX2 P34913 2/20 0.44
AADAT Q8N5Z0 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
MMP1 P03956 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530837 0.84 EPHX2 (0.44) PLAUPLATF10EPHX2PSEN1
SCHEMBL4526832 0.81 EPHX2 (0.43) PLAUPLATEPHX2PSEN1PSEN2
SCHEMBL3825976 0.79 FABP4 (0.49) PLAUPLATF10EPHX2PSEN1
SCHEMBL3829057 0.77 SMN1; SMN2 (0.46) PLAUPLATF10PSEN1PSEN2
SCHEMBL3831673 0.75 FABP4 (0.47) PLAUF10EPHX2PSEN1PSEN2
SCHEMBL3831668 0.75 FABP4 (0.47) PLAUF10EPHX2PSEN1PSEN2
SCHEMBL3956313 0.75 GAA (0.62) FKBP1AGAAALDH1A1CYP3A4CYP2C9
SCHEMBL2437981 0.73 MMP1 (0.58) FKBP1AGAAALDH1A1MMP1MMP3
SCHEMBL13964823 0.72 ALDH1A1 (0.55) FKBP1AALDH1A1PKMMMP1MMP3
SCHEMBL3826016 0.70 PLAU (0.44) PLAUPLATF10GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099747-A1 RADIOLABELLING VIA FLUORINATION OF AZIRIDINES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 EP disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
WO-2008083729-A1 RADIOLABELLING VIA FLUORINATION OF AZIRIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-17 WO disclosed
EP-1944288-A1 Radiolabelling via fluorination of aziridines Bayer Schering Pharma Aktiengesellschaft (DE) 2008-07-16 EP disclosed
EP-1944288-A1 Radiolabelling via fluorination of aziridines Bayer Schering Pharma Aktiengesellschaft (DE) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090022664-A1 Radiolabelling via fluorination of aziridines TMEM14C, ARFGEF1, NPFFR1 PLAU 4306/4885PLAT 3836/4885F10 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.